Zobrazeno 21 - 30
of 106
pro vyhledávání: '"Achim Rittmeyer"'
Autor:
Siow-Ming Lee, Christian Schulz, Kumar Prabhash, Dariusz Kowalski, Aleksandra Szczesna, Baohui Han, Achim Rittmeyer, Toby Talbot, David Vicente, Raffaele Califano, Diego Cortinovis, Anh Tuan Le, Dingzhi Huang, Geoffrey Liu, Federico Cappuzzo, Jessica Reyes Contreras, Martin Reck, Ramon Palmero, Milena Perez Mak, Youyou Hu, Stefanie Morris, Elen Höglander, Mary Connors, Alice M. Biggane, Hans Kristian Vollan, solange peters
Publikováno v:
SSRN Electronic Journal.
Autor:
Kirsten Reuter-Jessen, Tessa Rosenthal, Laura Lukat, Annalen Bleckmann, Sara Hugo, Katja Schmitz, Achim Rittmeyer, Juliane Schnalke, Hans-Ulrich Schildhaus, Marc Hinterthaner, Wolfgang Körber, Dana Alina Cron, Joachim Moecks, Tabea Hugo, Tobias Overbeck
Publikováno v:
Translational Lung Cancer Research. 9:603-616
Ca Schildhaus Background: MET amplifications occur in human tumors, including non-small cell lung cancer (NSCLC). MET inhibitors have demonstrated some clinical activity in MET amplified NSCLC, presumably with a gene dose effect. However, the definit
Autor:
E Bloch, Paul Martin Putora, S Andreas, Achim Rittmeyer, Ralf Dressel, Markus Glatzer, E Garelli
Publikováno v:
Garelli, Elena; Rittmeyer, Achim; Putora, Paul Martin; Glatzer, Markus; Dressel, Ralf; Andreas, Stefan (2019). Abscopal effect in lung cancer: three case reports and a concise review. Immunotherapy, 11(17), pp. 1445-1461. Future Medicine Ltd 10.2217/imt-2019-0105
The abscopal effect describes the ability of locally administered radiotherapy to induce systemic antitumor effects. Over the past 40 years, reports on the abscopal effect following conventional radiation have been relatively rare, especially in less
Autor:
Markus Harden, Christian Reinhardt, Stefan Andreas, Achim Rittmeyer, Christoph Herrmann-Lingen
The authors have requested that this preprint be removed from Research Square.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f573d6c2ab12d43eba3776c5fc6f113e
https://doi.org/10.21203/rs.3.rs-1013438/v1
https://doi.org/10.21203/rs.3.rs-1013438/v1
Autor:
Charles M. Rudin, Stephen V. Liu, Shun Lu, Ross A. Soo, Min Hee Hong, Jong-Seok Lee, Maciej Bryl, Daphne W Dumoulin, Achim Rittmeyer, Chao-Hua Chiu, Ozgur Ozyilkan, Alejandro Navarro, Silvia Novello, Yuichi Ozawa, Raymond Meng, Tien Hoang, Anthony Lee, Xiaohui Wen, Meilin Huang, Martin Reck
Publikováno v:
Journal of Clinical Oncology. 40:LBA8507-LBA8507
LBA8507 Background: Atezo, in combination with CE, was the first cancer immunotherapy approved for 1L treatment of ES-SCLC. However, most pts eventually experience disease progression. TIGIT is a novel inhibitory immune checkpoint present on activate
Autor:
Afshin Dowlati, Oscar Juan-Vidal, Sandrine Hiret, Achim Rittmeyer, Shawgi Sukumaran, David Vicente Baz, Jorge Arturo Rios-Perez, Eric Michael Harris, Steven L. McCune, Melissa Lynne Johnson, Brandon Croft, Jesse S. McGreivy, Wayne P. Rothbaum, Javier de Castro Carpeño
Publikováno v:
Journal of Clinical Oncology. 40:TPS8600-TPS8600
TPS8600 Background: Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumor characterized by early metastasis and a high recurrence rate with currently available treatment options. Although SCLC is generally sensitive to initial che
Autor:
Wolfgang M. Brueckl, Gunther H. Wiest, C. Wesseler, Amanda Tufman, Petra Hoffknecht, Eckart Laack, Martin Reck, Jens Kollmeier, Achim Rittmeyer, Fabian Reich, Petros Christopoulos, Bernhard Ulm, Joachim H. Ficker, Albrecht Stenzinger
Publikováno v:
Transl Lung Cancer Res
Background Chemotherapy plus immune-checkpoint inhibitor (CTx+ICI) therapy has become the preferred 1st line treatment in patients with metastatic NSCLC without oncogenic driven mutations. However, the optimal subsequent 2nd line treatment is not def
Autor:
David R. Gandara, S. Morris, A. Cardona, Julien Mazieres, Martin Reck, Marcus Ballinger, Diana Mendus, Denis Moro-Sibilot, Shirish M. Gadgeel, Achim Rittmeyer, Solange Peters
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Journal for immunotherapy of cancer, vol 9, iss 3
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol 9, iss 3
Journal for Immunotherapy of Cancer
BackgroundTreatment-induced accelerated tumor growth is a progression pattern reported with immune checkpoint inhibitors that has never been evaluated in randomized phase III studies because it requires two pretreatment scans. This study aimed to dev
Autor:
Michael McCleod, Alona Zer, Steven L. McCune, Marcin Kowanetz, Henry Jacob Conter, Hans-Georg Kopp, Tarek Mekhail, Niels Reinmuth, W. Lin, Ahad Sadiq, Lijia Wang, Alan Sandler, Maen A. Hussein, Federico Cappuzzo, V. Archer, Achim Rittmeyer, Davey B. Daniel, Howard Jack West, Tania Ochi Lohmann, Alessandro Morabito
Publikováno v:
The Lancet Oncology. 20:924-937
Summary Background Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved overall survival in patients with previously treated non-small-cell lung cancer and also showed clinical benefit when combined with ch
Autor:
Markus Glatzer, Martin Früh, Paul Martin Putora, Marco Radovic, Ravindran Kanesvaran, Fabrizio Minervini, Achim Rittmeyer
Publikováno v:
Journal of Geriatric Oncology. 10:405-410
Lung cancer is the leading cause of cancer death worldwide. Older patients represent approximately half of the patient population and optimal management of these patients is challenging. In early-stagenon-small cell lung cancer (NSCLC), lobectomy sho